Abstract: Wide surgical resection or a marginal/incomplete resection followed by full-course radiation therapy is the current standard of care for canine soft tissue sarcoma. The purpose of this retrospective, descriptive, bi-institutional study was to determine the effectiveness and toxicity of a hypofractionated 5 × 6 Gy protocol on macroscopic canine soft tissue sarcoma in terms of progression-free interval (PFI) and overall survival (OS), and to identify prognostic factors for patient outcome. Dogs with macroscopic soft tissue sarcoma irradiated with 5 × 6 Gy were eligible for the study. Progression-free interval and OS were compared with respect to different tumor and patient characteristics by the Kaplan-Meier method and multivariable Cox regression analysis. Fifty dogs with macroscopic disease were included. All dogs received the same radiation therapy protocol; part of the group (n = 20) received postradiation metronomic chemotherapy. Median PFI for all cases was 419 days (95% confidence interval (CI): 287-551) and median OS was 513 days (95% CI: 368-658). Dogs with tumors on the limbs had significantly longer PFI and OS, compared with head or trunk. Increasing tumor burden decreased OS. The addition of metronomic chemotherapy yielded a significantly longer OS (757 days (95% CI: 570-944) compared with dogs that did not receive systemic treatment (286 days (95% CI: 0-518), (P = 0.023)), but did not influence progression-free interval. Toxicity was low throughout all treatments. The 5 × 6 Gy radiation therapy protocol was well tolerated and provided long PFI and OS in dogs with macroscopic soft tissue sarcoma. 
Introduction

47!
Soft tissue sarcomas refer to a group of malignant tumors that arise from mesenchymal cells 48! and can occur in any part of the body, most commonly in the extremities and trunk. Although 49! canine soft tissue sarcomas present with wide variations in subtypes (fibrosarcoma, 50! perivascular wall tumors, peripheral nerve sheet tumors, liposarcoma, myxosarcoma, 51! malignant mesenchymoma) 1, 2 , these tumors tend to have a similar biologic behavior, 52! consisting of locally invasive growth and usually a low-to-intermediate metastatic potential.
53!
Conversely, other mesenchymal tumors also arising from soft tissues, including 54! hemangiosarcoma, histiocytic sarcoma and rhabdomyosarcoma, have a more aggressive 55! biologic behavior and a higher tendency to spread.
3 Surgery with or without full-course post-56! operative radiation therapy is the mainstay of treatment of canine soft tissue sarcomas.
2, 4-6
57!
Adequate treatment yields long survival times ranging from 1416 3 to 2270 days 4, 5 , with only 58! 33% of the cases succumbing to the disease. However, analyses of prognostic factors showed 59! that the extent of resection, initial tumor size, anatomical location, histological grade and 60! clinical stage were predictive of outcome. [3] [4] [5] It is well documented that the extent of resection 61! is associated with local control of soft tissue sarcoma. 6, 7 However, one study describes that 62! some of these tumors resected without an adequate margin of normal tissue may only have a 63! failure rate of about 30%. 8 Unfortunately, in some clinical situations, surgery cannot be used 64! without unacceptable morbidity, or gross disease is left behind at resection in an attempt to 65! spare critical normal structures or avoid amputation in the case of soft tissue sarcoma located 66! on the extremities. 67! Hypofractionated radiation therapy protocols for macroscopic or microscopic canine soft 68! tissue sarcomas are currently used in a true palliative (e.g. providing pain relief and 69! improvement of dysfunction) 9, 10 setting for elderly patients or patients presenting with serious 70! co-morbidities, but also due to financial restraint of owners or logistical restraint of treatment 71! ! 4! machine availability. [11] [12] [13] The responses in the macroscopic setting using a 4x8 Gy weekly 72! protocol have been found to be rather short-lived with about 5 months of median time to 73! 
Discussion
281!
The present study is based on a large number of dogs with soft tissue sarcoma with 282! macroscopic (unresected or recurrent) disease treated with a hypofractionated 5x6 Gy 283! radiation therapy protocol. For several reasons, such as financial or logistical restraints of the 284! owners, co-morbidities of the patients amongst others, there seems to be a demand for non-285! curative approach for the treatment of canine soft tissue sarcoma. In a previous study, a 4x8 286! Gy palliative protocol for macroscopic disease revealed short progression free interval of 5.2 287! months and overall survival of 10.3 months.
11 The progression free interval and overall 288! survival from the current study population were higher, with progression free interval of 13.9 289! months and overall survival of 17.1 months. Limb tumors fared significantly better with 290! progression free interval of 15.5 months regardless of tumor burden, histology or grade. The 291! general finding of long progression free interval and overall survival was surprising, as a 292! satisfactory outcome of radiation therapy alone for soft tissue sarcoma is not usually expected, 293! due to the rather low radioresponsiveness of sarcomas. Also, although the great majority of 294! dogs obtained stable disease at the end of radiation therapy, 10% and 20% of the treated cases 295! obtained complete responses and partial responses, respectively. Interestingly, the response 296! rate further improved over time, highlighting that neoplastic cells keep dying off for months 297! after the end of radiation treatment or respond slowly to metronomic chemotherapy.
298!
The commonly used term "canine soft tissue sarcoma" is used for tumors with similar 299! biologic behavior.
2, 30 However, while not described for surgical or multimodal curative 300! approach 3-5 , tumors on the limbs might respond better to hypofractionated protocols 12 , or the 301! limb location displays simply less discomfort for the patient.
11 Furthermore, this result may be 302! attributable to the fact that the majority of limb soft tissue sarcomas are histologically 303! described as perivascular wall tumors.
1 Compared to anaplastic sarcomas, it is known that 304! they usually have less expansile growth with less tissue infiltration, low to no local aggressive 305! ! 14! behavior with recurrence developing after a long latency, and low tendency to metastasize.
1, 31
306! 307! Management of recurrent tumors is often more difficult, and this study showed that more than 308! one previous surgery in dogs presenting with macroscopic disease drastically reduced 309! progression free interval to 3.4 months, while overall survival was not influenced. Multiple 310! excisions may disrupt or contaminate the tissue planes, cause damage to existing vasculature 311! with possible subsequent tissue hypoxia and could hypothetically lead to a selection pressure 312! of cells with a higher malignancy in the recurrent tumor. Furthermore, recurrence of 313! incompletely excised soft tissue sarcomas has been linked to histological grade 32 , with a low 314! recurrence rate to be expected in a microscopic disease setting of mostly low-grade soft tissue 315! sarcomas. 12 The results of the current study also support this finding.
316!
Larger tumor size is in general considered a poor predictive factor 2, 6 , however, while most 317! likely influencing the probability for complete surgical excision, size itself has not been 318! identified as a prognostic factor in various studies. 30, 32, 33 In this study, increasing tumor 319! volume decreased overall survival, perhaps indicating that larger tumors cause greater 320! discomfort and prompt owners into the decision of euthanasia earlier.
321! 322!
Metronomic chemotherapy refers to the frequent administration of cytotoxic drugs at doses 323! significantly less than the maximum tolerated dose, with no prolonged drug-free breaks, 324! leading to an anti-angiogenic effect and immune-modulation. 34 Unlike traditional 325! chemotherapy, the main targets of which are proliferating tumor cells, the main targets of 326! metronomic chemotherapy are the endothelial cells of the growing vasculature of a tumor. 34 
327!
Although the use of dose-intense chemotherapy has been controversial in dogs with soft tissue 328! sarcomas, the addition of metronomic chemotherapy has been recently described in the 329! microscopic setting, leading to significantly prolonged disease-free intervals compared to a 330! ! 15! nonrandomized control group. 14 In the current study, dogs receiving metronomic 331! chemotherapy had a significant improvement in overall survival, whereas the progression free 332! interval was not increased. Although encouraging, this finding needs to be interpreted 333! cautiously. First, it should be borne in mind that OS may not be the best endpoint in 334! veterinary oncology, as it may be influenced by tumor-unrelated factors, such as owners' 335! financial concern or logistic issues, leading to premature euthanasia. Second, dogs receiving 336! metronomic chemotherapy were younger than those that only received radiation therapy, and 337! it may be possible that owners of younger dogs were more motivated in treating their animals 338! than owners of elderly patients, which may have elected euthanasia sooner. Several reasons 339! may explain why elderly dogs are less likely to receive chemotherapy, including the presence 340! of concomitant diseases and the owner' unwillingness to accept possible negative effects of 341! systemic treatment.
342!
Interestingly, some dogs receiving metronomic chemotherapy experienced an improved 343! response rate over time, with 3 cases obtaining complete response after partial response (n=2) 344! or stable disease (n=1), and 1 case obtaining partial response after having achieved stable 345! disease at the end of radiation therapy. Whether the addition of metronomic chemotherapy 346! after radiation therapy is superior to radiation therapy alone needs to be tested in prospective 347! trials. With this premise in mind, this study indicates that metronomic chemotherapy warrants 348! further prospective investigation in canine soft tissue sarcoma to answer several questions. size -are also expected to a lower degree than in the prior described 4x8 to 9 Gy protocols. 
364!
Due to the retrospective nature of this study, the use of archival data, and considering the 365! well-known difficulty of proper clinical assessment of response of soft tissue sarcoma to 366! radiation therapy, the authors may not have been able to describe the full range of 367! improvement in these dogs and some of the information had to be gathered by telephone 368! follow-up, possibly skewing the information by owner's perception. Furthermore, different 369! pathologists made the diagnoses and histological grade was only available in 84% of the 370! cases. The modified stage grouping could only be applied in patients with known grade. 22 As 371! most of the patients were of stage I disease and the prognostic significance of the staging 372! system for soft tissue sarcoma has not been further investigated 2 , the TNM was excluded from 373! statistical description. The bi-institutionality of the study is of minor concern, as the treatment 374! planning was either done remotely (all photon plans) or under the direct supervision (electron 375! hand calculations) by the same radiation oncologist (CRB). 
